{"id":"2264de37-ff53-5fcf-bb6b-394ff34d1b32","stable_key":"ff370329-68a3-573d-96ee-597de78a3967:api-cd26","predicate":"increases_in_recorded_comparison","statement":"Apigenin increased cell-surface CD26/DPP4 expression in HT-29 cells.","claim_class":"observational","status":"source_recorded","evidence_grade":"ungraded","direction":"positive","is_public":true,"mechanism_event_id":"64add17b-b013-5059-982e-1519995ec025","mechanism_event_label":"Apigenin increased cell-surface CD26/DPP4 expression in HT-29 cells.","subject":{"id":"4425961f-4764-56d3-9887-87e47749379b","slug":"apigenin","display_name":"Apigenin","entity_type_key":"small_molecule"},"object":{"id":"a8650e3d-e30f-5fcf-8811-2d4055819356","slug":"human-dpp4","display_name":"Human dipeptidyl peptidase 4 / DPP4 / CD26","entity_type_key":"protein"},"evidence_count":1,"mechanism_event":{"id":"64add17b-b013-5059-982e-1519995ec025","stable_key":"ff370329-68a3-573d-96ee-597de78a3967:api-cd26-event","event_type":"experimental_observation","label":"Apigenin increased cell-surface CD26/DPP4 expression in HT-29 cells.","description":"### api-cd26\n\nApigenin increased cell-surface CD26/DPP4 expression in HT-29 cells.\nSurface expression is not necessarily catalytic activity, glucose control or an anti-tumor endpoint.\nModel and exposure: Human colorectal cancer cell line; 30–60 micromolar, 48 hours.\nLimitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.\nReference: Apigenin directly interacts with and inhibits topoisomerase 1 to upregulate CD26/DPP4 on colorectal carcinoma cells. | 2022 | https://pubmed.ncbi.nlm.nih.gov/36618939/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC9815539/ | https://doi.org/10.3389/fphar.2022.1086894 | Access: Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"4425961f-4764-56d3-9887-87e47749379b","slug":"apigenin","display_name":"Apigenin","entity_type_key":"small_molecule"},"role":"tested factor","stoichiometry":null,"state_label":"Apigenin","sequence_order":0,"notes":""},{"entity":{"id":"a8650e3d-e30f-5fcf-8811-2d4055819356","slug":"human-dpp4","display_name":"Human dipeptidyl peptidase 4 / DPP4 / CD26","entity_type_key":"protein"},"role":"measured outcome","stoichiometry":null,"state_label":"increase","sequence_order":1,"notes":""}]},"contexts":[{"dimension":"evidence_access","value_text":"Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_contrast","value_text":"{\"intervention\": \"Apigenin\", \"comparator\": \"Vehicle\", \"endpoint\": \"Apigenin increased cell-surface CD26/DPP4 expression in HT-29 cells.\", \"effect_direction\": \"increase\", \"combination\": \"single\", \"conditions\": []}","comparator":null,"unit":null,"notes":"Explicit extracted experimental comparison; recorded from source.","entity":null},{"dimension":"experimental_model","value_text":"Human colorectal cancer cell line; 30–60 micromolar, 48 hours.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"interpretation_status","value_text":"Recorded from source with stated access limits; ungraded, not independent replication.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Apigenin collection; exact intervention and molecular form govern interpretation.","comparator":null,"unit":null,"notes":"","entity":{"slug":"apigenin","display_name":"Apigenin","entity_type_key":"small_molecule"}},{"dimension":"plain_language","value_text":"Apigenin increased cell-surface CD26/DPP4 expression in HT-29 cells.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"Apigenin directly interacts with and inhibits topoisomerase 1 to upregulate CD26/DPP4 on colorectal carcinoma cells. | https://pubmed.ncbi.nlm.nih.gov/36618939/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC9815539/ | https://doi.org/10.3389/fphar.2022.1086894","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"source_locator","value_text":"Reviewed reference api-cd26; Surface expression is not necessarily catalytic activity, glucose control or an anti-tumor endpoint.","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"15af4f48-6e0f-5507-8a6e-e31648d03f4f","evidence_kind":"source_excerpt","locator":"Lines 724-730","start_line":724,"end_line":730,"excerpt":"### api-cd26\n\nApigenin increased cell-surface CD26/DPP4 expression in HT-29 cells.\nSurface expression is not necessarily catalytic activity, glucose control or an anti-tumor endpoint.\nModel and exposure: Human colorectal cancer cell line; 30–60 micromolar, 48 hours.\nLimitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.\nReference: Apigenin directly interacts with and inhibits topoisomerase 1 to upregulate CD26/DPP4 on colorectal carcinoma cells. | 2022 | https://pubmed.ncbi.nlm.nih.gov/36618939/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC9815539/ | https://doi.org/10.3389/fphar.2022.1086894 | Access: Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.","model_system":"Human colorectal cancer cell line; 30–60 micromolar, 48 hours.","directness":"reported_statement","verification_status":"source_recorded","notes":"Original paraphrase in the retained reviewed reference, not a verbatim primary-paper quotation. Access level is explicit.","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"54eac90b-add1-5f56-9036-d900307c5697","stable_key":"import-ff370329-68a3-573d-96ee-597de78a3967","title":"Apigenin: detailed mechanisms of action (reviewed 10 October 2026)","document_type":"imported_text","citation_label":"AI-assisted original curation of primary studies; claim-local access and experimental limitations stated. Includes original-draft correction history. No independent replication claimed.","file_path":"","sha256":"ede6e5c6b91d66b66844f2ff667a7f8303d9ac1281f15dc09db703f7de4da942","revision_id":"b41a39a2-0197-549c-97a5-1765e6696931","review_status":"source_recorded","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}